Pulmonx, Inc.

42 articles about Pulmonx, Inc.

• Pulmonx to Report First Quarter 2023 Financial Results on May 2, 2023

  4/18/2023

  Pulmonx Corporation, a global leader in minimally invasive treatments for lung disease, announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May 2, 2023.

• American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema

  12/14/2022

  Pulmonx Corporation has partnered with American Lung Association to provide education to patients and providers on Endobronchial Valves, a clinically proven treatment to help people with severe COPD/emphysema breathe easier.1 COPD has no cure and is the third leading cause of death worldwide.

• Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

  11/30/2022

  Pulmonx Corporation announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the Zephyr ® Endobronchial Valve for treating severe COPD/emphysema patients.

• Pulmonx to Present at Upcoming September 2022 Investor Conferences

  8/24/2022

  Pulmonx Corporation a global leader in minimally invasive treatments for severe lung disease, announced the company will be participating in fireside chats at two upcoming investor conferences.

• Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022

  7/19/2022

  Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022.

• Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment

  9/21/2021

  Pulmonx Corporation, a global leader in minimally invasive treatments for severe lung disease, announced that Blue Cross Blue Shield Michigan and Horizon BCBS have issued positive coverage policies for endobronchial valves, such as the Zephyr® Endobronchial Valve, for severe emphysema, a form of COPD.

• Pulmonx Announces National Reimbursement in France for Zephyr Endobronchial Valves, a Revolutionary Treatment Option for Patients With Severe Emphysema/COPD

  5/18/2020

  Pulmonx Corporation announced today that the French Health Ministry has granted national reimbursement for the Zephyr Endobronchial Valve, the first minimally-invasive treatment option for patients with severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). The Zephyr Valve procedure, done through a simple bronchoscopy with no incision or cutting, is clinically proven to improve patients’ breathing

• 

  Clinical Catch-Up: May 11-15

  5/18/2020

  Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.

• Pulmonx Secures $66M in Financing to Support Commercial Acceleration of the Zephyr Valve System, a Minimally-Invasive Treatment for Severe Emphysema

  5/5/2020

  Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor. The financing also attracted new investors Adage Capital Management, HealthQuest Capital, Partner Fund Management, and Rock Springs Capital, as well as existing investors. I

• Pulmonx Names Industry Veteran to Board of Directors

  2/26/2020

  Feb. 26, 2020 15:30 UTC REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, today announced that Daniel Florin has joined its Board of Directors. Mr. Florin has been serving as Executive Vice President at Zimmer Biomet Holdings Inc. since July 2019 (NYSE: ZBH). Previously, he served as Executive Vice President and Chief Financial Officer of Z

• Pulmonx Announces that UnitedHealthcare, the Largest Commercial Insurer in the United States, Has Lifted Coverage Restrictions on the Zephyr Valve, a Minimally-Invasive Treatment Option for Severe Emphysema (COPD)

  11/18/2019

  Both UnitedHealthcare® and EmblemHealth recently announced positive coverage updates for Endobronchial Valve Treatment

• Ally Bridge Group Leads Pulmonx's $65 Million Financing, Further Strengthening Its Global Medtech Franchise

  5/10/2019

  Ally Bridge Group announced that it led an over-subscribed $65 million financing of Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies with its key product approved and marketed in the US, Europe, Australia, and Asia, including China.

• Pulmonx Announces That HUMANA Has Issued a Positive Coverage Policy for the Zephyr Valve, a Less Invasive Treatment Option for Severe Emphysema (COPD)

  4/30/2019

  Humana® is the second major insurer to post a coverage policy for Pulmonx’s Zephyr Endobronchial Valve Treatment

• National Institute for Health and Care Excellence (NICE) Issues New Guidelines for COPD, Recommending Severe Patients be Evaluated for Bronchoscopic Lung Volume Reduction

  12/11/2018

  NICE makes a “strong” recommendation that patients with severe COPD be referred for evaluation for bronchoscopic lung volume reduction, including the Zephyr® Endobronchial Valve System.

• Pulmonx Announces that One of the Leading Health Care Providers in the United States Now Covers the Zephyr Valve for Bronchoscopic Lung Volume Reduction in Patients with Severe Emphysema

  11/15/2018

  Coverage decision aligns with the FDA's decision to approve the Zephyr Valves under the “Breakthrough Devices” status.

• FDA Approves Zephyr Endobronchial Valve for Treating Severe Emphysema

  6/29/2018

  Pulmonx® Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System.

• Pulmonx Submits Premarket Approval (PMA) Application to U.S. FDA for Zephyr Endobronchial Valve as Treatment for Emphysema

  1/9/2018

  The filing was based on the successful execution of Pulmonx’s pivotal IDE trial, the LIBERATE Study, a landmark randomized controlled trial that enrolled 190 patients with severe emphysema at 24 centers in the U.S. and Europe.

• U.K. NICE Updates Endobronchial Valve Treatment Guidance to Standard Care

  1/4/2018

  Pulmonx, today announced that the UK's NICE has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of COPD, and now considers current evidence sufficient to support routine use.

• Pulmonx, Inc. Release: New Study Demonstrates Zephyr Endobronchial Valves Significantly Improve Breathing, Mobility And Quality Of Life For Emphysema Patients

  9/11/2017

• Pulmonx, Inc. Release: New Data From Two Multi-Center Randomized Clinical Trials Demonstrate That Zephyr Endobronchial Valves Deliver Benefit To Both Heterogeneous And Homogenous Emphysema Patients Without Collateral Ventilation

  5/24/2017